A multicentre prospective study on pemetrexed in the second line chemotherapy of non small cell lung cancer. Data from routine clinical practice

• Authors: KOLEK V.; PEŠEK M.; GRYGÁRKOVÁ I.; ZATLOUKAL P.; SKŘIČKOVÁ Jana; SIXTOVÁ D.; KOUBKOVÁ L.; ROUBEC J.; SALAJKA F.; PETRUŽELKA L.; VYZULA Rostislav; ŠTÍCHA M.
• Year of publication: 2012
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine

Attached files

• Skrickovlung_cancer_001.pdf

• Description: Non small cell lung cancer (NSCLC) is one of the most aggressive tumours with unsatisfactory prognosis and extremely high mortality. Pemetrexed and platinum became one of the therapeutic options in advanced NSCLC in routine practice. It is recommended both in the 1st and 2nd lines of chemotherapy.